Home » Archive by Category


San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Waiting Period Ends for Proposed CareFusion, Becton Deal

November 20, 2014 – 6:01 pm | Edit Post

Becton, Dickinson and Co. and CareFusion Corp. announced that the waiting period mandated under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 regarding Becton’s proposed acquisition of San Diego-based CareFusion expired on Nov. 19.

BioNano Raises $53M to Identify “Structural Variations” in Genome

November 20, 2014 – 5:44 pm | Edit Post

[Corrected 11/24/14, 12 pm. See below.] San Diego-based BioNano Genomics, which has taken a fundamentally different approach to analyzing the genome, says today it has closed on $53 million in Series…

[[Click headline to continue reading.]]

Cytori Therapeutics, Inc. Announces Promising Results In A Feasibility Trial Of Cell Therapy In Conjunction With Anterior Cruciate Ligament Repair

November 20, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Cytori Therapeutics, Inc. (NASDAQ: CYTX) today reported positive results from a clinical study of Cytori Cell Therapy in anterior cruciate ligament (ACL) reconstruction of patients with ACL tears. The 6 month results from the first 20 patients with combination Cytori Cell Therapy and bone-patellar tendon-bone (BPTB) grafts were presented at the Barcelona Knee Symposium…

<i>Time</i> Magazine Names The Aethlon Medical Hemopurifier One Of The 25 Best Inventions Of 2014

November 20, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 21, 2014 /PRNewswire/ — Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier has been named one of the 25 best inventions of 2014 by Time Magazine. The article…

Salk scientist receives 2014 Ray Thomas Edwards Foundation Career Development Award

November 20, 2014 – 5:00 pm | Edit Post

Janelle Ayres, Salk assistant professor in the Nomis Foundation Laboratories for Immunobiology and Microbial Pathogenesis, has been selected to receive the prestigious Ray Thomas Edwards Foundation Career Development Award. Only one three-year grant is conferred annually, aiming to foster the development of a promising early career biomedical researcher in San Diego County and to help him or her make the transition to becoming an independent investigator.

Tandem Diabetes Care Announces Partnership With To Further Expand Access To Diabetes Device Data

November 20, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 21, 2014 /PRNewswire/ –Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim Insulin Pump, today announced a partnership with Tidepool, a non-profit dedicated to improving diabetes therapy management by offering an open…

Orexigen Therapeutics, Inc. Announces Allowance Of New U.S. Patent For Contrave (Naltrexone Hcl / Bupropion Hcl Extended Release)

November 20, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 21, 2014 /PRNewswire/ –Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for U.S. Patent Application No. 11/757,773, which covers use of Orexigen’s sustained release formulation of naltrexone…

SpectraScience, Inc. To Present At Conference On December 3rd

November 20, 2014 – 5:00 pm | Edit Post

SAN DIEGO, CA–(Marketwired – November 19, 2014) – SpectraScience, Inc. (OTCQB: SCIE), a San Diego-based medical device company, today announced that Michael Oliver, President and Chief Executive Officer, will make a presentation at the LD Micro conference on Wednesday, December 3rd, 2014 at 9:30 AM PST / …

REVA Medical Closes Financing

November 20, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce that the financing transaction approved by the Company’s shareholders at the Special Meeting of Stockholders held in Sydney, Australia on October 31, 2014, has been successfully…

Isis Pharmaceuticals, Inc. Release: ISIS-STAT3 Rx And ISIS-AR Rx Data Presented By AstraZeneca PLC At

November 20, 2014 – 5:00 pm | Edit Post

CARLSBAD, Calif., Nov. 20, 2014 /PRNewswire/ –Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from two drugs in its anti-cancer franchise will be presented by researchers at AstraZeneca in three presentations at the 26th European Organization for Research and Treatment of Cancer…